MC
ALNY icon

Maverick Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Maverick Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,983
Closed -$752K – 328
2021
Q3 		$752K Sell
3,983
-288,700
-99% -$54.2M 0.01% 381
2021
Q2 		$49.6M Sell
292,683
-503,551
-63% -$73.8M 0.47% 38
2021
Q1 		$112M Sell
796,234
-188,268
-19% -$28.3M 1.04% 19
2020
Q4 		$128M Buy
984,502
+17,041
+2% +$2.28M 2.05% 18
2020
Q3 		$141M Sell
967,461
-146,147
-13% -$20.8M 2.62% 11
2020
Q2 		$165M Sell
1,113,608
-226,097
-17% -$30.5M 3.47% 10
2020
Q1 		$146M Sell
1,339,705
-921,192
-41% -$106M 3.08% 11
2019
Q4 		$260M Sell
2,260,897
-961,916
-30% -$95.9M 3.79% 7
2019
Q3 		$259M Sell
3,222,813
-1,013,203
-24% -$80.2M 3.81% 7
2019
Q2 		$307M Buy
4,236,016
+1,025,629
+32% +$78.7M 4.45% 7
2019
Q1 		$300M Buy
3,210,387
+406,436
+14% +$34M 3.98% 4
2018
Q4 		$204M Buy
2,803,951
+1,291,887
+85% +$99.4M 3% 10
2018
Q3 		$132M Buy
1,512,064
+830,710
+122% +$83.6M 1.65% 22
2018
Q2 		$67.1M Buy
+681,354
New +$67.6M 0.78% 27

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Maverick Capital's ALNY Position: Q4 2021 in Review

Maverick Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 3,983 shares — an estimated $752K sold.

Maverick Capital first reported a position in ALNY in Q2 2018 and held it in 14 quarters. The position peaked at $307M in Q2 2019. 433 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Maverick Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 3,983 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $752K.
  • Maverick Capital first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 14 quarters.
  • Maverick Capital's Alnylam Pharmaceuticals position peaked at $307M in Q2 2019.
  • 433 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.